These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 23685020)

  • 1. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.
    Goyal J; Pond GR; Galsky MD; Hendricks R; Small A; Tsao CK; Sonpavde G
    Urol Oncol; 2014 Jan; 32(1):36.e27-34. PubMed ID: 23685020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
    Pond GR; Armstrong AJ; Wood BA; Leopold L; Galsky MD; Sonpavde G
    BJU Int; 2012 Dec; 110(11 Pt B):E461-8. PubMed ID: 22520631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
    Pond GR; Berry WR; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Clin Genitourin Cancer; 2012 Dec; 10(4):239-45. PubMed ID: 23000202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
    Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
    J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
    Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
    Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
    van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
    Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
    Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
    Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
    Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
    Pond GR; Sonpavde G; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
    Eur Urol; 2014 Jan; 65(1):3-6. PubMed ID: 24120464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
    Sonpavde G; Pond GR; Armstrong AJ; Galsky MD; Leopold L; Wood BA; Wang SL; Paolini J; Chen I; Chow-Maneval E; Mooney DJ; Lechuga M; Smith MR; Michaelson MD
    BJU Int; 2014 Dec; 114(6b):E25-E31. PubMed ID: 24298897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncological Outcome of Docetaxel-Based Chemotherapy for Men with Metastatic Castration-Resistant Prostate Cancer.
    Bejrananda T; Pripatnanont C; Tanthanuch M; Karnjanawanichkul W
    J Med Assoc Thai; 2016 Dec; 99(12):1315-21. PubMed ID: 29952517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
    Armstrong AJ; Tannock IF; de Wit R; George DJ; Eisenberger M; Halabi S
    Eur J Cancer; 2010 Feb; 46(3):517-25. PubMed ID: 20005697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
    Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
    BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
    Guinney J; Wang T; Laajala TD; Winner KK; Bare JC; Neto EC; Khan SA; Peddinti G; Airola A; Pahikkala T; Mirtti T; Yu T; Bot BM; Shen L; Abdallah K; Norman T; Friend S; Stolovitzky G; Soule H; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Xie Y; Aittokallio T; Zhou FL; Costello JC;
    Lancet Oncol; 2017 Jan; 18(1):132-142. PubMed ID: 27864015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?
    Kongsted P; Svane IM; Lindberg H; Daugaard G; Sengeløv L
    Urol Oncol; 2015 Nov; 33(11):494.e15-20. PubMed ID: 26254696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
    Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.
    Caffo O; Ortega C; Di Lorenzo G; Sava T; De Giorgi U; Cavaliere C; Macrini S; Spizzo G; Aieta M; Messina C; Tucci M; Lodde M; Mansueto G; Zucali PA; Alesini D; D'Angelo A; Massari F; Morelli F; Procopio G; Ratta R; Fratino L; Lo Re G; Pegoraro MC; Zustovich F; Vicario G; Ruatta F; Federico P; La Russa F; Burgio SL; Maines F; Veccia A; Galligioni E
    Urol Oncol; 2015 Jun; 33(6):265.e15-21. PubMed ID: 25907622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
    Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
    BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.